From the top 120 candidates tested in qMSP, 72 were validated (PCa n = 50; controls n = 35), leading to a panel of 14/72 DMGs (including AKR1B1HES5, CHST11, GAS6, GRASP, ITPRIPL1, KCNB2, MAX.chr3.6187, AX.chr3.8028, SCOL3A1, SERPINB9, ST6GALNAC2, WNT3A, and ZNF655) after multiplexing and filtering for its use in liquid biopsy. The gene discussed is WNT3A; the disease is posterior cortical atrophy.